Sevirumab  (Synonyms: MSL-109)

Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC₅₀ of 0.3 μg/mL^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

EC50: 0.3 μg/mL (CMV)^[1]

Sevirumab (MSL-109) perturbs the gH/gL homodimer rather than abolishing dimerization. Sevirumab may be splaying the dimer apart at sufficient distance to reduce fluorescence resonance energy transfer (FRET) and ultimately prevent proper gH/gL function^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

138660-96-5

[Sevirumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994 May;24(1):17-26.  [Content Brief]

  [2]. Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8209-14.  [Content Brief]